The Brief

President Donald Trump announced a new agreement with Eli Lilly and Novo Nordisk to expand coverage and lower prices for popular obesity drugs Zepbound and Wegovy, part of the GLP-1 class of treatments.

The deal builds on Trump’s ongoing efforts to cut drug costs, following an executive order requiring drug companies to lower prices or face new federal payment limits.

While broader access and lower prices are expected next year, it remains unclear how much individual consumers will actually save, given insurance variations and market competition.

WASHINGTON - President Donald Trump announced a deal on Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices on popular obesity drugs.

The obsesity treatements Zepbound and Wegovy are part of a

See Full Page